

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner

v.

ALCON RESEARCH, LTD.,
Patent Owner.

Case IPR2017-01053
U.S. Patent No. 8,268,299

DECLARATION OF HENRY GRABOWSKI, Ph.D.

TABLE OF CONTENTS

| | | |
|------|---|----|
| I. | Introduction..... | 3 |
| A. | Qualifications | 3 |
| B. | Assignment..... | 5 |
| C. | Summary of Opinions | 14 |
| II. | Treatment of Glaucoma with Ophthalmic Prostaglandin Analog Drugs | 16 |
| III. | TRAVATAN Z [®] Is a Commercial Success..... | 20 |
| IV. | There Is a Nexus between the Commercial Success of TRAVATAN Z [®] and the Patent at Issue | 26 |
| A. | TRAVATAN Z [®] 's Patented Features | 26 |
| B. | Alcon's Promotion of TRAVATAN Z [®] Is Comparable to That of Other Branded Ophthalmic Prostaglandin Analogs..... | 30 |
| 1. | Marketing and Promotional Activities in the Pharmaceutical Industry | 30 |
| 2. | The Extent of Promotional Activities for TRAVATAN Z [®] | 31 |
| C. | Alcon's Practice of Offering Copayment Coupons for TRAVATAN Z [®] Is Consistent with Practices of Manufacturers of Other Branded Ophthalmic Prostaglandin Analogs..... | 36 |
| 1. | Manufacturer-Sponsored Copayment Coupon Programs in the Pharmaceutical Industry..... | 36 |
| 2. | Copayment Coupons for TRAVATAN Z [®] and Other Prostaglandin Analogs | 37 |
| D. | TRAVATAN Z [®] 's Formulary Placement Reflects the Value That TRAVATAN Z [®] Provides to Patients..... | 40 |

I, Henry Grabowski, hereby declare as follows:

I. Introduction

1. I am over the age of eighteen (18) and otherwise competent to make this declaration.

2. I understand that the Patent Trial and Appeal Board has granted Argentum Pharmaceuticals LLC's ("Argentum") petition to institute this Inter Partes Review ("IPR") regarding claims 1–28 of United States Patent No. 8,268,299 (the "'299 patent") on obviousness grounds.

A. Qualifications

3. I am currently Professor Emeritus of Economics and the Director of the Program in Pharmaceuticals and Health Economics at Duke University. I received my Bachelor of Science degree in Engineering Physics from Lehigh University in 1962. In 1967, I obtained a doctorate in Economics from Princeton University. My academic and research specialties are in the pharmaceutical industry—health economics, economics of innovation, and government regulation.

4. I have studied the economics of the pharmaceutical industry over much of my career, and I have published numerous articles and books on this industry. I created a graduate course at Duke on economics and policy issues in the pharmaceutical industry. Under a series of grants from the National Science Foundation, I have examined the economics of pharmaceutical research and

development (“R&D”) and the effect of various government policy actions on drug innovation. I have testified several times before Congressional committees in the United States on pharmaceutical industry issues. For example, since 1994, I have testified on issues involving effective patent life and generic competition in pharmaceuticals, generic biologics, the Clinton Administration’s health reform legislation, and the federal government’s policy toward children’s vaccines.

5. I have been an advisor and consultant to the National Academy of Sciences, Institute of Medicine, Federal Trade Commission, General Accounting Office, and Office of Technology Assessment. I have also held visiting scholar appointments at the International Institute of Management in Berlin, Germany, Health Care Financing Administration in Washington, D.C., the Office of Health Economics in London, and the Centre for Medicines Research in London. Until its acquisition by Gilead Sciences in 2003, I served on the Board of Directors of Triangle Pharmaceuticals, Inc., a development-stage company that specialized in antiviral drug therapies.

6. I have done extensive research on the economics of competition in the pharmaceutical industry, including the role of patents and the importance of R&D. I have also performed several studies on pharmaceutical R&D costs and profits. The Congressional Budget Office has used my work in this regard to analyze the effects of the Drug Price Competition and Patent Term Restoration Act

(“Hatch-Waxman Act”) on R&D returns and to analyze the proposed changes associated with the Health Security Act of 1993.

7. Exhibit 2030 is a copy of my curriculum vitae, which includes a more detailed description of my education and professional experience, as well as a list of my publications from the last forty years.

B. Assignment

8. I have been retained by Williams & Connolly LLP on behalf of Alcon Research, Ltd. (“Alcon”) to serve as an expert witness in this action.

9. In particular, I have been asked to opine on whether Alcon’s drug, TRAVATAN Z[®], is a commercial success, and if so, to address the factors underlying its commercial success, including whether there is a nexus between its commercial success and the features of the claimed invention. I have also been asked to opine on whether Alcon’s promotional activities for TRAVATAN Z[®] are in line with that of other products in the same therapeutic category.

10. In connection with the opinions and conclusions contained within this declaration, listed below are the documents that I have reviewed and considered or created (based on data from IQVIA—formerly IMS Health—and Encuity Research, which I understand are being provided to Argentum). I have also relied on my training, my years of experience as an economist, my regular review and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.